**Supplementary Table 1.** Preferred Term (PT) affected by ADRs and drug classes mostly involved.

|  |  |  |
| --- | --- | --- |
| **Preferred Term (PT)a** | ***n* (%)b** | **Drug classes (ATC III)c** |
| Tinnitus | 358 (54.9) | L01X-other antineoplastic agents (33); M01A -antiinflammatory and antirheumatic products non–steroids (23); B01A-antithrombotic agents (22) |
| Hypoacusis (incl. neurosensory hypoacusis) | 213 (32.7) | L01X-other antineoplastic agents (42); L04A-immunosuppressants (22); J01F-macrolides, lincosamides and streptogramins (16); L01C- plant alkaloids and other natural products (16) |
| Vertigo positional | 34 (5.2) | N03A-antiepileptics (7); N06A –antidepressants (5); J04A-drugs for treatment of tuberculosis (3); N02A-opioids (3); B01A-antithrombotic agents (3) |
| Auditory disorder | 23 (3.5) | N05A-antipsychotics (5); J01M-quinolone antibacterials (3); M01A-antiinflammatory and antirheumatic products non–steroids (3) |
| Deafness (incl. deafness bilateral, deafness neurosensory, deafness unilateral and sudden hearing loss) | 22 (3.4) | L01X-other antineoplastic agents (4); J01G-aminoglycoside antibacterials (3); J01M-quinolone antibacterials (2); J01X-other antibacterials (2); G04B-urologicals (2) |

*ADR* Adverse Drug Reaction, *ATC* Anatomical Therapeutic Chemical Classification System

*aOnly Preferred Term (PT) accounting for twenty or more reports related to ototoxicity were considered*

*bThe sum of the distribution of ototoxic ADR reports by PT (%) is higher than the total number of reports, since a single report could contain more than one ADRs related to the selected PTs*

*cOnly top three drug classes (n>1) reported for each PT were considered. In some cases, more drug categories were simultaneously involved*